☰

Shili Xu, Ph.D. - Publications

Affiliations: 
2013 Pharmaceutical Sciences University of Southern California, Los Angeles, CA, United States 
Area:
Pharmacy, Oncology
Tree Info Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Li R, Ong SL, Tran LM, Jing Z, Liu B, Park SJ, Huang ZL, Walser TC, Heinrich EL, Lee G, Salehi-Rad R, Crosson WP, Pagano PC, Paul MK, Xu S, et al. Author Correction: Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. Scientific Reports. 10: 4386. PMID 32127587 DOI: 10.1038/S41598-020-61341-3  0.312
2020 Li R, Ong SL, Tran LM, Jing Z, Liu B, Park SJ, Huang ZL, Walser TC, Heinrich EL, Lee G, Salehi-Rad R, Crosson WP, Pagano PC, Paul MK, Xu S, et al. Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. Scientific Reports. 10: 377. PMID 31941995 DOI: 10.1038/S41598-019-57285-Y  0.347
2020 Kim SS, Xu S, Cui J, Poddar S, Le TM, Hayrapetyan H, Li L, Wu N, Moore AM, Zhou L, Yu AC, Dann AM, Elliott IA, Abt ER, Kim W, et al. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression. Theranostics. 10: 829-840. PMID 31903153 DOI: 10.7150/Thno.40195  0.411
2020 Moore AM, Zhou L, Xu S, Donahue TR. Abstract 6045: Interferon signaling induces NAD(H) consumption via PARP9/10/14 and sensitizes pancreatic cancer cells to NAMPT inhibition Cancer Research. 80: 6045-6045. DOI: 10.1158/1538-7445.Am2020-6045  0.427
2019 Abt ER, Rosser EW, Durst MA, Lok V, Poddar S, Le TM, Cho A, Kim W, Wei L, Song J, Capri JR, Xu S, Wu N, Slavik R, Jung ME, et al. Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. Cell Chemical Biology. PMID 31734178 DOI: 10.1016/J.Chembiol.2019.10.012  0.363
2019 Xu S, Herschman HR. A tumor agnostic therapeutic strategy for Hexokinase 1 Null/Hexokinase 2 positive cancers. Cancer Research. PMID 31434645 DOI: 10.1158/0008-5472.Can-19-1789  0.44
2019 Xu S, Liu Y, Yang K, Wang H, Shergalis A, Kyani A, Bankhead A, Tamura S, Yang S, Wang X, Wang CC, Rehemtulla A, Ljungman M, Neamati N. Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes. Theranostics. 9: 2282-2298. PMID 31149044 DOI: 10.7150/Thno.30621  0.573
2019 Machiraju PK, Yedla P, Gubbala SP, Bohari T, Abdul JKV, Xu S, Patel R, Chittireddy VRR, Boppana K, Jagarlapudi SARP, Neamati N, Syed R, Amanchy R. Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design. Computational Biology and Chemistry. 80: 374-383. PMID 31103918 DOI: 10.1016/J.Compbiolchem.2019.04.015  0.597
2019 Elliott IA, Dann AM, Xu S, Kim SS, Abt ER, Kim W, Poddar S, Moore A, Zhou L, Williams JL, Capri JR, Ghukasyan R, Matsumura C, Tucker DA, Armstrong WR, et al. Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Proceedings of the National Academy of Sciences of the United States of America. PMID 30894490 DOI: 10.1073/Pnas.1812410116  0.417
2019 Xu S, Zhou T, Doh HM, Trinh KR, Catapang A, Lee JT, Braas D, Bayley NA, Yamada RE, Vasuthasawat A, Sasine JP, Timmerman JM, Larson SM, Kim Y, Macleod AR, et al. An HK2 antisense oligonucleotide induces synthetic lethality in HK1-HK2+ multiple myeloma. Cancer Research. PMID 30885978 DOI: 10.1158/0008-5472.Can-18-2799  0.43
2019 Xu S, Elliott IA, Dann AM, Kim SS, Abe ER, Kim W, Poddar S, Moore A, Zhou L, Williams JL, Capri JR, Ghukasyan R, Matsumura C, Tucker DA, Armstrong WR, et al. Abstract 4264: Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion Cancer Research. 79: 4264-4264. DOI: 10.1158/1538-7445.Am2019-4264  0.426
2018 Xu S, Catapang A, Braas D, Stiles L, Doh HM, Lee JT, Graeber TG, Damoiseaux R, Shirihai O, Herschman HR. A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers. Cancer & Metabolism. 6: 7. PMID 29988332 DOI: 10.1186/S40170-018-0181-8  0.427
2018 Xu S, Catapang A, Doh HM, Bayley NA, Lee JT, Braas D, Graeber TG, Herschman HR. Hexokinase 2 is targetable for HK1 negative, HK2 positive tumors from a wide variety of tissues of origin. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29880505 DOI: 10.2967/Jnumed.118.212365  0.38
2017 Xu S, Catapang A, Braas D, Stiles L, Lee JT, Graeber TG, Damoiseaux R, Shirihai O, Herschman HR. Abstract B37: Targeting the energy generation triangle to achieve synthetic lethality for treatment of hepatocellular carcinoma Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-B37  0.368
2016 Krall AS, Xu S, Graeber TG, Braas D, Christofk HR. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nature Communications. 7: 11457. PMID 27126896 DOI: 10.1038/Ncomms11457  0.314
2015 Xu S, Adisetiyo H, Tamura S, Grande F, Garofalo A, Roy-Burman P, Neamati N. Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer. British Journal of Cancer. 113: 242-51. PMID 26103574 DOI: 10.1038/Bjc.2015.228  0.519
2015 Prevost GP, Garrido M, Xu S, Lefebvre C, Chauchereau A, Carniato D, Briand JF, Gutmann M, Serova M, Tijeras-Raballand A, Grammont AD, Raymond E, Gespach C, Sabbah M, Neamati N, et al. Abstract 4466: New biomarkers to optimize preclinical development of the PDI inhibitor XCE853 Cancer Research. 75: 4466-4466. DOI: 10.1158/1538-7445.Am2015-4466  0.483
2014 Singh SS, Sarma JA, Narasu L, Dayam R, Xu S, Neamati N. A review on PARP1 inhibitors: Pharmacophore modeling, virtual and biological screening studies to identify novel PARP1 inhibitors. Current Topics in Medicinal Chemistry. 14: 2020-30. PMID 25262797 DOI: 10.2174/1568026614666140929152123  0.577
2014 Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discovery Today. 19: 222-40. PMID 24184531 DOI: 10.1016/J.Drudis.2013.10.017  0.605
2014 Prevost GP, Xu S, Garrido M, Serova M, Vewer OD, Gespach C, Briand J, Tijeras-Raballand A, Gutmann M, Hendrix A, Sabbah M, Chachereau A, Gramont Ad, Neamati N, Carniato D, et al. Abstract 1812: XCE853: A novel PDI inhibitor that inhibits proliferation of human tumor cellsin vitro,ex-vivoandin vivo Cancer Research. 74: 1812-1812. DOI: 10.1158/1538-7445.Am2014-1812  0.449
2013 Xu S, Neamati N. gp130: a promising drug target for cancer therapy. Expert Opinion On Therapeutic Targets. 17: 1303-28. PMID 24099136 DOI: 10.1517/14728222.2013.830105  0.561
2013 Adisetiyo H, Liang M, Liao CP, Aycock-Williams A, Cohen MB, Xu S, Neamati N, Conway EM, Cheng CY, Nikitin AY, Roy-Burman P. Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma. Plos One. 8: e69484. PMID 23936028 DOI: 10.1371/Journal.Pone.0069484  0.515
2013 Saha S, Reddy ChV, Xu S, Sankar S, Neamati N, Patro B. Synthesis and SAR studies of marine natural products ma'edamines A, B and their analogues. Bioorganic & Medicinal Chemistry Letters. 23: 5135-9. PMID 23927972 DOI: 10.1016/J.Bmcl.2013.07.017  0.515
2013 Xu S, Grande F, Garofalo A, Neamati N. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Molecular Cancer Therapeutics. 12: 937-49. PMID 23536726 DOI: 10.1158/1535-7163.Mct-12-1082  0.628
2013 Xu S, Oshima T, Imada T, Masuda M, Debnath B, Grande F, Garofalo A, Neamati N. Stabilization of MDA-7/IL-24 for colon cancer therapy. Cancer Letters. 335: 421-30. PMID 23481022 DOI: 10.1016/J.Canlet.2013.02.055  0.562
2013 Debnath B, Xu S, Grande F, Garofalo A, Neamati N. Small molecule inhibitors of CXCR4. Theranostics. 3: 47-75. PMID 23382786 DOI: 10.7150/Thno.5376  0.569
2013 Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA, Neamati N. Abstract 5513: Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase (PDI) for ovarian cancer treatment. Cancer Research. 73: 5513-5513. DOI: 10.1158/1538-7445.Am2013-5513  0.435
2012 Zeng LF, Wang Y, Kazemi R, Xu S, Xu ZL, Sanchez TW, Yang LM, Debnath B, Odde S, Xie H, Zheng YT, Ding J, Neamati N, Long YQ. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. Journal of Medicinal Chemistry. 55: 9492-509. PMID 23098137 DOI: 10.1021/Jm300667V  0.693
2012 Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA, Neamati N. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proceedings of the National Academy of Sciences of the United States of America. 109: 16348-53. PMID 22988091 DOI: 10.1073/Pnas.1205226109  0.635
2012 Debnath B, Xu S, Neamati N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. Journal of Medicinal Chemistry. 55: 6645-68. PMID 22650325 DOI: 10.1021/Jm300207S  0.526
2012 Yamada R, Xu S, Neamati N. Abstract 2908: Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery Cancer Research. 72: 2908-2908. DOI: 10.1158/1538-7445.Am2012-2908  0.416
2012 Xu S, Oshima T, Grande F, Neamati N, Garofalo A. Abstract 1927: Mechanistic characterization of SC144 in colon cancer Cancer Research. 72: 1927-1927. DOI: 10.1158/1538-7445.Am2012-1927  0.6
2011 Millard M, Pathania D, Grande F, Xu S, Neamati N. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. Current Pharmaceutical Design. 17: 536-59. PMID 21391905 DOI: 10.2174/138161211795222649  0.692
2011 Xu S, Grande F, Garofalo A, Neamati N. Abstract C148: SC144: The first orally active small molecule gp130 inhibitor for the treatment of ovarian cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C148  0.623
2010 Yamada R, Kostova MB, Anchoori RK, Xu S, Neamati N, Khan SR. Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery. Cancer Biology & Therapy. 9: 192-203. PMID 20023432 DOI: 10.4161/Cbt.9.3.10656  0.556
Show low-probability matches.